Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:
马萨诸塞州沃尔塞姆,2024年11月27日(环球新闻通讯社)-- Apellis制药公司(纳斯达克:APLS)今天宣布公司将参加以下12月份的投资者会议:
- Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 9:10 a.m. ET
- Citi Global Healthcare Conference: Fireside chat on Thursday, December 5, 2024, at 1:00 p.m. ET
- Evercore ISI HealthCONx Conference: 2024年12月4日(星期三)上午9:10举行炉边聊天
- 花旗全球卫生保健会议: 2024年12月5日(星期四)下午1:00举行炉边聊天
The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 90 days following the event.
现场会议网络直播将发布在公司网站的“投资者与媒体”版块的“事件和演讲”页面上。回放将在活动结束后大约90天内提供。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
关于Apellis
Apellis Pharmaceuticals是一家全球生物制药公司,结合勇敢的科学和同情心,为一些最具挑战性的疾病患者开发改变生命的治疗方案。我们推出了15年来第一个新的补体药物系,现有两种针对C3的批准药物,其中包括全球首款用于地理萎缩症的治疗。我们相信,我们才刚刚开始释放针对C3治疗严重眼部、罕见和神经系统疾病的潜力。欲了解更多信息,请访问或关注我们的Twitter和LinkedIn。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投资者联系:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178